Calcium-phosphate homeostasis in secondary progressive multiple sclerosis patients during mitoxantrone therapy

DISCUSSION: Deficiency of VitD was observed at the baseline in most SPMS patients eligible for MTX therapy. Due to adverse reactions to MTX treatment, this therapy requires patient compliance, cautious drug administration and monitoring during the therapy.PMID:34240684 | DOI:10.1080/01616412.2021.1949683

Source: Neurological Research - July 9, 2021 Category: Neurology Authors: Martyna Lis Natalia Niedziela Maria Nowak-Kiczmer Katarzyna Kubicka-B ączyk Monika Adamczyk-Sowa Source Type: research